Design for the EMA [Regulatives / Guidelines]

posted by ryraman2661 – India, 2023-05-15 15:03 (400 d 01:44 ago) – Posting: # 23554
Views: 1,854

Dear Members,

I have one point to be discussed in the forum.

For Bioequivalence studies for EU submission, can we compare capsules VS tablets of same drug, and same strength.

If yes, whether both Cmax and AUC (total) to be included in the criteria? or we can compare only AUC (total).
What are the others points to be taken care.

Members can give their opinion.

Thanks

Raman
Chennai


Edit: Subject line changed; see also this post #2. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,057 posts in 4,840 threads, 1,641 registered users;
75 visitors (0 registered, 75 guests [including 6 identified bots]).
Forum time: 16:48 CEST (Europe/Vienna)

You should treat as many patients as possible with the new drugs
while they still have the power to heal.    Armand Trousseau

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5